Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

05/09/2024 30 min
Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD

Listen "Emerging Cell Therapies for Blood Cancers with Arcellx CMO, Chris Heery, MD"

Episode Synopsis

In this podcast episode, we sit down with Christopher Heery, the Chief Medical Officer at Arcellx to learn about the company's pipeline and lead cell therapy, anitocabtagene autoleucel, or anito-cel, that is in development for multiple myeloma.

Multiple myeloma, like lymphoma and leukemia are types of cancer that start in your blood cells.

More episodes of the podcast Rx for Biotech